Related references
Note: Only part of the references are listed.Five hub genes contributing to the oncogenesis and trastuzumab-resistance in gastric cancer
Fahai Chen et al.
GENE (2023)
Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial
Kensei Yamaguchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Zanidatamab + chemotherapy as first-line treatment for HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA).
Elena Elimova et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial
Josep Tabernero et al.
GASTRIC CANCER (2023)
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02) : primary and updated analyses from a single-arm, phase 2
Eric Van Cutsem et al.
LANCET ONCOLOGY (2023)
Research progress of antibody-drug conjugates therapy for HER2-low expressing gastric cancer
Minghui Yu et al.
TRANSLATIONAL ONCOLOGY (2023)
Antibody-drug conjugates: the clinical development in gastric cancer
Yingze Zhu et al.
FRONTIERS IN ONCOLOGY (2023)
MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma-Trial in progress
Daniel V. T. Catenacci et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs
Elena Diaz-Rodriguez et al.
CANCERS (2022)
Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: A systematic review
Dionne Blange et al.
CANCER TREATMENT REVIEWS (2022)
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
HER2 Inhibition in Gastric Cancer-Novel Therapeutic Approaches for an Established Target
Caroline Fong et al.
CANCERS (2022)
Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma
Yang Zhang et al.
CELL REPORTS MEDICINE (2022)
HERIZON-GEA-01: Zanidatamab plus chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma
Josep Tabernero et al.
FUTURE ONCOLOGY (2022)
Margetuximab with retifanlimab as first-line therapy in HER2D/PD-L1D unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A
D. V. T. Catenacci et al.
ESMO OPEN (2022)
Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers
K. Jhaveri et al.
ANNALS OF ONCOLOGY (2022)
MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma
Daniel V. T. Catenacci et al.
FUTURE ONCOLOGY (2021)
Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study.
Funda Meric-Bernstam et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
Yelena Y. Janjigian et al.
NATURE (2021)
Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study
Zhi Peng et al.
CANCER COMMUNICATIONS (2021)
The preliminary efficacy of KN026 (Anti-HER2 BsAb) in advanced gastric and gastroesophageal junction cancer patients with HER2 expression.
Jianming Xu et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).
Kensei Yamaguchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial
Daniel V. T. Catenacci et al.
LANCET ONCOLOGY (2020)
Intratumoral and intertumoral heterogeneity of HER2 immunohistochemical expression in gastric cancer
He Zhang et al.
PATHOLOGY RESEARCH AND PRACTICE (2020)
HER2 Heterogeneity in Personalized Therapy of Gastro-Oesophageal Malignancies: An Overview by Different Methodologies
Antonio Ieni et al.
JOURNAL OF PERSONALIZED MEDICINE (2020)
Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer
Manish A. Shah et al.
GASTRIC CANCER (2019)
HER2 testing in gastric cancer diagnosis: insights on variables influencing HER2-positivity from a large, multicenter, observational study in Germany
Gustavo Baretton et al.
VIRCHOWS ARCHIV (2019)
HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
Akio Kaito et al.
WORLD JOURNAL OF CLINICAL CASES (2019)
Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)
Seyoung Seo et al.
GASTRIC CANCER (2019)
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
Peter C. Thuss-Patience et al.
LANCET ONCOLOGY (2017)
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research
F. Pietrantonio et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC-A Randomized Phase III Trial
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTANA- A Randomized, Phase III Study
Taroh Satoh et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)